Cure8 research brief
Genetic variants (especially NUDT15) can raise the risk of dangerous low blood counts from thiopurine drugs. Knowing a patient's genotype before starting azathioprine/mercaptopurine could help prevent myelosuppression.
Adult IBD patients considering or receiving thiopurines (azathioprine/mercaptopurine), gastroenterology clinicians, and researchers interested in pharmacogenetics of IBD.
This retrospective cohort of 124 Thai IBD patients treated with azathioprine measured TPMT and NUDT15 polymorphisms and tracked myelosuppression over about 7.6 years. NUDT15 variants occurred in ~16.9% of patients and were significantly associated with TIM; TPMT variants were less common (~4.8%) and not significantly linked to TIM in this sample.
The single patient with homozygous NUDT15 mutation developed TIM within the first month. If you or your clinician are considering thiopurines, local prevalence of these variants, availability of genetic testing, and cost-effectiveness are important factors when deciding about pre-treatment genotyping.
This is a retrospective single-country cohort (Thailand) with 124 patients; findings reflect local variant prevalence and may not generalize. The article is an abstract-level structured report from Crohn's & Colitis 360 (full-text extracted here is an abstract).
The study supports consideration of genotyping but does not provide cost-effectiveness data or prospective trial results.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The review links specific therapies and surgical options to outcomes that matter to people with IBD — mucosal healing, lower hospitalizations, and reduced need for surgery — and highlights that combining medical and...
This study suggests LVV can occur in people with IBD at younger ages and with distinct vascular findings, and it may arise even when gut disease is in remission. That matters for awareness, diagnosis, and coordination...
People with IBD and their clinicians need to know whether common IBD treatments change COVID-19 risk or should be stopped. This review provides practical recommendations (continue most maintenance drugs; avoid systemic...
